Chemotherapy‐induced peripheral neurotoxicity can be misdiagnosed by the National Cancer Institute Common Toxicity scale
- 1 September 2011
- journal article
- Published by Wiley in Journal of the Peripheral Nervous System
- Vol. 16 (3) , 228-236
Abstract
The assessment of chemotherapy‐induced peripheral neurotoxicity (CIPN) is still uncertain as several of the most frequently used scales do not rely on a formal neurological evaluation and depend on patients' reports and examiners' interpretations. The aim of this study was to compare the assessment of CIPN using the National Cancer Institute Common Toxicity Criteria (NCI‐CTC) scale and a formal neurological assessment scored with the Total Neuropathy Score (TNS, i.e., a composite scale designed to grade the impairment in neuropathy patients) to identify possible discrepancies in the diagnosis. In this prospective study, 155 patients treated with cisplatin/carboplatin or with paclitaxel/docetaxel and CIPN were examined in a collaborative oncological/neurological multi‐center trial using the NCI‐CTC scale and the TNS; the results were then extensively compared. We evidenced that the TNS allows possible misdiagnosed neuropathies to be revealed. In fact, the NCI‐CTC evaluation performed by experienced examiners overestimated the occurrence of motor neuropathy, possibly because of the presence of confounding factors (e.g., fatigue, depression, cachexia), which might be difficult to be ruled out without a formal neurological examination. This study strongly indicates that a more formal neurological assessment of patients with CIPN than that achievable with the common toxicity scales (e.g., NCI‐CTC) is advisable.Keywords
This publication has 34 references indexed in Scilit:
- Long‐term neurologic and peripheral vascular toxicity after chemotherapy treatment of testicular cancerCancer, 2010
- Neurological monitoring reduces the incidence of bortezomib‐induced peripheral neuropathy in multiple myeloma patientsJournal of the Peripheral Nervous System, 2010
- Role of a pre‐existing neuropathy on the course of bortezomib‐induced peripheral neurotoxicityJournal of the Peripheral Nervous System, 2008
- Peripheral nerve damage associated with administration of taxanes in patients with cancerCritical Reviews in Oncology/Hematology, 2008
- Chemotherapy‐induced neuropathyJournal of the Peripheral Nervous System, 2008
- NCI-CTC vs TNS: which tool is better for grading the severity of chemotherapy-induced peripheral neuropathy?Nature Clinical Practice Neurology, 2008
- The Usefulness of Nerve Conduction Studies in Objectively Assessing Oxaliplatin-Induced Peripheral NeuropathyThe Oncologist, 2007
- The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy‐induced peripheral neurotoxicity: comparison with the National Cancer Institute‐Common Toxicity ScaleJournal of the Peripheral Nervous System, 2007
- Peripheral neuropathy induced by administration of cisplatin- and paclitaxel-based chemotherapy. Could it be predicted?Supportive Care in Cancer, 2005
- Simplified Calculation of Body-Surface AreaNew England Journal of Medicine, 1987